The Formulary is our regular review of pharmacotherapy, or treatment with pharmaceutical drugs. Bookmark this page to keep up to date with the latest developments in drugs and drug treatment, and browse previous instalments of Formulary from the British Journal of Family Medicine archive.
Empagliflozin receives expansion of indication to reduce CV death
The European Commission has approved an update to the label of SGLT2 inhibitor empagliflozin (Jardiance) to include a change to the indication statement, meaning it is now indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise.
Treatments for cancer, cholesterol and chronic migraines among medicines accepted for routine use by NHS Scotland
Beta blockers offer best chance of increased heart attack survival
Lithium still the best drug to avoid hospital admissions for people with bipolar, says research
Scottish Medicines consortium accepts four new medicines
Benzodiazepines increase stroke risk among Alzheimer’s patients
Scottish Medicines Consortium accepts prostate cancer drug, rejects other treatments
Drug offers hope for patients suffering from peripheral-vestibular vertigo
The drug Arevert (dimenhydrinate 40mg), used for the treatment of peripheral-vestibular vertigo associated with Ménière-like symptoms, was significantly superior to betahistine in relieving symptoms of the condition when used in combination with cinnarizine 20mg, pharmaceutical Hennig Arzneimittel has announced.